共 113 条
[1]
Lipton S(2012)The new ASAS classification criteria for axial and peripheral spondyloarthritis Int J Clin Rheumatol 6 675-682
[2]
Deodhar A(2011)Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden Ann Rheum Dis 70 624-629
[3]
Neovius M(2014)The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug BMC Musculoskelet Disord 23 452-528
[4]
Simard JF(2014)Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis Ann Rheum Dis 73 516-904
[5]
Askling J(2011)2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis Ann Rheum Dis 70 896-12
[6]
Navarro Coy NC(2012)European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies Ann Rheum Dis 71 4-151
[7]
Brown S(1993)What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 19 123-15
[8]
Bosworth A(2016)Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Ann Rheum Dis 75 3-93
[9]
Nam JL(2005)External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 365 82-534
[10]
Ramiro S(2016)Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases Rheumatology (Oxford) 55 523-1638